Burgess Paul D. 4
4 · Cerevel Therapeutics Holdings, Inc. · Filed Dec 21, 2023
Insider Transaction Report
Form 4
Burgess Paul D.
See Remarks
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-12-19−23,847→ 0 total→ Common Stock (23,847 underlying) - Exercise/Conversion
Common Stock
2023-12-19+23,847→ 45,727 total
Footnotes (2)
- [F1]In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the "Issuer"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units ("RSUs") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest.
- [F2]Each RSU represented the contingent right to receive one share of the Issuer's common stock.